PI3K inhibitors in inflammation, autoimmunity and cancer.
about
The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersAdvances in Autophagy Regulatory MechanismsMetabolomics in rheumatic diseases: desperately seeking biomarkersInflammatory bowel disease: can omega-3 fatty acids really help?ISA-2011B, a Phosphatidylinositol 4-Phosphate 5-Kinase α Inhibitor, Impairs CD28-Dependent Costimulatory and Pro-inflammatory Signals in Human T Lymphocytes.Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.Negative regulation of TLR signaling in myeloid cells--implications for autoimmune diseases.Effect of different concentrations of omega-3 fatty acids on stimulated THP-1 macrophages.Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.Pyridazinone: an attractive lead for anti-inflammatory and analgesic drug discovery.Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion.Investigation into the Role of PI3K and JAK3 Kinase Inhibitors in Murine Models of Asthma.Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis comparable with mechanisms seen in inflammatory pathways? Part I: historical observations and clinical perspectives on the etiology of increased CSF protein levelInteraction of molecular alterations with immune response in melanoma.Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.Bioelectrical signals improve cardiac function and modify gene expression of extracellular matrix componentsCharacterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances.Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.A Study of the Differential Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Gene Expression Profiles of Stimulated Thp-1 Macrophages.Autophagy and airway fibrosis: Is there a link?The effect and possible clinical efficacy of in vivo inhibition of neutrophil extracellular traps by blockade of PI3K-gamma on the pathogenesis of microscopic polyangiitis.Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.A novel PI3K axis selective molecule exhibits potent tumor inhibition in colorectal carcinogenesis.Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs.Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.Molecular Genetic and Epigenetic Basis of Multiple Sclerosis.Macrophages and the Recovery from Acute and Chronic Inflammation.Targeting the class IA PI3K isoforms p110α/δ attenuates heart allograft rejection in mice by suppressing the CD4+ T lymphocyte response.MicroRNA Expression Profiling in Behçet's Disease.Cancer; an induced disease of twentieth century! Induction of tolerance, increased entropy and 'Dark Energy': loss of biorhythms (Anabolism v. Catabolism).PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner
P2860
Q26747403-D514BB92-C329-4F35-A8D8-029EC1D6C0A7Q26748934-E49A47C9-99FB-49E4-8D2D-19AF0FC86E86Q26765005-0A1AA157-23DF-4032-8436-A452795DE8ACQ26769891-F543615C-1876-4015-A1A3-B509123F89ADQ33603302-C86F6D1F-4736-4C7C-A0CA-F02AEDE9DF28Q36244592-A8D80F3A-C749-4233-A3AA-D3957056D0D2Q36437284-DE6B2034-E3DF-46C2-A2AD-81A9B9CE3332Q37658502-6B708D5F-FFE8-4399-B1A4-5870672736F1Q38684394-4356AC75-25A3-4C7A-B88A-FF7A010E0C4BQ38702479-A65376D7-CDCD-461E-8421-7ACB02188BACQ38783636-9F46B515-F4F2-4959-ABC0-F32252AF070AQ38785807-268305BB-E47B-41F4-8FB5-1E27580AC3CAQ38908177-AA125ED6-2FCB-4824-B8AF-E3966FC2D39DQ39098904-9560816E-4C67-4562-9D56-93DE8C181F20Q39164918-DADCAF0D-BA7E-48C6-A814-E740E600722BQ39329609-C206F37B-D372-4543-8A2D-0A4D711EA5D3Q39413866-504B92CD-8FD7-4FB3-82E6-ED7CCACD3E68Q41239295-A1F57EA5-4D02-4DF6-A9D0-3374EC721E81Q41561599-5F2CF5EE-2E79-48C6-B97D-0B263EDD8E68Q41872185-3470E357-BEC4-444B-BFF5-2C9940D343ACQ41991078-2D21D44F-36ED-4E10-BC88-2B2760EF6914Q42233437-34DF6A4F-F156-4027-98DF-9E2A62417319Q42289683-9923B4F7-CA55-47D0-B190-F927C91B6EADQ46310887-B6DEB114-E6CB-42CD-9ACF-62A4256E9856Q46430396-7809B118-52C9-4850-978C-28746BAA7240Q46611154-F66F0B36-5263-46B7-B482-18C5182E93C8Q47134013-7C2AC52A-3ABD-4DEE-90C9-C1ED79049F25Q47137924-194A0996-2FE2-4DA1-996E-AE2401465605Q48019225-4C7A680E-18CC-41CA-9061-06ECD2098F5BQ48354362-58BF3D13-BD4A-4D04-A491-1338D972B04AQ51270292-40D97722-2810-4BE5-AF5E-4084D411E9C1Q54976588-ECDAA231-6412-4CDB-B765-1C2F1A3C4544Q55101372-60D491E9-2D14-49F3-8127-8420A01D6A9AQ55709806-BE027ADA-AADE-464F-9764-6726507553CBQ58793836-53E44E67-645E-43C6-AC51-611400B1CD14
P2860
PI3K inhibitors in inflammation, autoimmunity and cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
PI3K inhibitors in inflammation, autoimmunity and cancer.
@en
type
label
PI3K inhibitors in inflammation, autoimmunity and cancer.
@en
prefLabel
PI3K inhibitors in inflammation, autoimmunity and cancer.
@en
P2860
P50
P921
P1476
PI3K inhibitors in inflammation, autoimmunity and cancer
@en
P2093
Anne-Katrien Stark
Srividya Sriskantharajah
P2860
P356
10.1016/J.COPH.2015.05.017
P5008
P577
2015-06-18T00:00:00Z